undefined undefined
NaN.000
NaN.00%
TD Cowen said in a note that recently approved gene therapies by Vertex Pharmaceuticals (NASDAQ:VRTX)/CRISPR (NASDAQ:CRSP) and bluebird bio (NASDAQ:BLUE) for sickle cell disease may get enhanced payme...
04-16 04:46
BOSTON, April 11, 2024 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, is hosting its 5th annual Ferment conf...
04-11 19:01
Needham:重申CRISPR Therapeutics(CRSP.US)评级,由买入调整至买入评级, 目标价90.00美元。
04-11 18:40
CRISPR Therapeutics (NASDAQ:CRSP) stock has been falling over the past month. W...
04-01 10:29
CRISPR gene editing technology has been heralded as a revolutionary breakthrough in drug development, enabling scientists to potentially cure genetic diseases by modifying the genes that cause them. T...
03-26 23:43
近年来,医疗健康产业创新不断涌现,并发展成为最活跃的行业之一,36氪见证和陪伴着这一领域创新企业的成长,并为行业带来专业的声音。 为此,36氪推出了“医疗健康行...
03-17 08:08
文|胡香赟 编辑|海若镜 2023年年底,美国FDA接连批准了两款CRISPR/Cas9基因编辑疗法上市,分别为福泰制药/CRISPR Therapeutic...
03-14 17:24
Investors with a lot of money to spend have taken a bearish stance on CRISPR Th...
02-23 02:16
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
02-22 20:23
Needham analyst Gil Blum maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.
02-22 00:40